Finally, our findings provided compelling evidence that the combined administration of CDK4/6-targeting inhibitors palbociclib and cisplatin effectively counteracted the oncogenic effects of IGF2BP3 and overcomes chemotherapy resistance in bladder cancer. This evidence concerns the gene IGF2BP3 and urinary bladder cancer.